Surrey Builds AI to Find Anti-Ageing Chemical Compounds

The University of Surrey has built an artificial intelligence (AI) model that identifies chemical compounds that promote healthy ageing - paving the way towards pharmaceutical innovations that extend a person's lifespan.

In a paper published by Nature Communication's Scientific Reports, a team of chemists from Surrey built a machine learning model based on the information from the DrugAge database to predict whether a compound can extend the life of Caenorhabditis elegans - a translucent worm that shares a similar metabolism to humans. The worm's shorter lifespan gave the researchers the opportunity to see the impact of the chemical compounds.

The AI singled out three compounds that have an 80 per cent chance of increasing the lifespan of elegans:

  • flavonoids (anti-oxidant pigments found in plants that promote cardiovascular health),
  • fatty acids (such as omega 3), and
  • Organooxygens (compounds that contain carbon to oxygen bonds, such as alcohol).

Sofia Kapsiani, co-author of the study and final year undergraduate student at the University of Surrey, said:

"Ageing is increasingly being recognised as a set of diseases in modern medicine, and we can apply the tools of the digital world, such as AI, to help slow down or protect against ageing and age-related diseases. Our study demonstrates the revolutionary ability of AI to aid the identification of compounds with anti-ageing properties."

Dr Brendan Howlin, lead author of the study and Senior Lecturer in Computational Chemistry at the University of Surrey, said:

"This research shows the power and potential of AI, which is a speciality of the University of Surrey, to drive significant benefits in human health."

Kapsiani S, Howlin BJ.
Random forest classification for predicting lifespan-extending chemical compounds.
Sci Rep. 2021 Jul 5;11(1):13812. doi: 10.1038/s41598-021-93070-6

Most Popular Now

Research Shows AI Technology Improves Pa…

Existing research indicates that the accuracy of a Parkinson's disease diagnosis hovers between 55% and 78% in the first five years of assessment. That's partly because Parkinson's sibling movement disorders...

Who's to Blame When AI Makes a Medi…

Assistive artificial intelligence technologies hold significant promise for transforming health care by aiding physicians in diagnosing, managing, and treating patients. However, the current trend of assistive AI implementation could actually...

First Therapy Chatbot Trial Shows AI can…

Dartmouth researchers conducted the first clinical trial of a therapy chatbot powered by generative AI and found that the software resulted in significant improvements in participants' symptoms, according to results...

DMEA sparks: The Future of Digital Healt…

8 - 10 April 2025, Berlin, Germany. Digitalization is considered one of the key strategies for addressing the shortage of skilled workers - but the digital health sector also needs qualified...

DeepSeek: The "Watson" to Doct…

DeepSeek is an artificial intelligence (AI) platform built on deep learning and natural language processing (NLP) technologies. Its core products include the DeepSeek-R1 and DeepSeek-V3 models. Leveraging an efficient Mixture...

Stepping Hill Hospital Announced as SPAR…

Stepping Hill Hospital, part of Stockport NHS Foundation Trust, has replaced its bedside units with state-of-the art devices running a full range of information, engagement, communications and productivity apps, to...

DMEA 2025: Digital Health Worldwide in B…

8 - 10 April 2025, Berlin, Germany. From the AI Act, to the potential of the European Health Data Space, to the power of patient data in Scandinavia - DMEA 2025...